Exelixis Announces June 24 Webcast of Presentation at the Piper Jaffray Europe Conference

SOUTH SAN FRANCISCO, Calif.--(Business Wire)--
Exelixis, Inc. (Nasdaq: EXEL) announced today that George A. Scangos, PhD, the
company`s president and chief executive officer, will present at the Piper
Jaffray Europe Conference at 3:30 p.m. UKT/10:30 a.m. EDT/7:30 a.m. PDT on
Wednesday, June 24, 2009. Dr. Scangos will discuss the company`s development
pipeline and corporate strategy.

The presentation will be webcast and may be accessed in the Event Calendar page
under Investors on the Exelixis website at www.exelixis.com.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the
discovery and development of novel small molecule therapeutics for the treatment
of cancer and other serious diseases. The company is leveraging its fully
integrated drug discovery platform to fuel the growth of its development
pipeline, which is primarily focused on cancer. Currently, Exelixis` broad
product pipeline includes investigational compounds in phase 3, phase 2, and
phase 1 clinical development. Exelixis has established strategic corporate
alliances with major pharmaceutical and biotechnology companies, including
Bristol-Myers Squibb, sanofi-aventis, GlaxoSmithKline, Genentech, Boehringer
Ingelheim, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For more information,
please visit the company`s web site at www.exelixis.com.

Exelixis, Inc.
Investor:
Charles Butler, 650-837-7277
Executive Director, Corporate Communications
cbutler@exelixis.com
or
Exelixis, Inc.
Media:
Soleil Maxwell Harrison, 650-837-7012
Senior Manager, Corporate Communications
sharrison@exelixis.com

Copyright Business Wire 2009